ClinicalTrials.gg
CompletedNCT03185819Updated Apr 29, 2025Results posted

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

A Phase 2 interventional study of Intranasal Placebo and Midazolam Placebo Solution in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 51 sites in 9 countries. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
9 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.

Enrollment
9th of 17
147 · median 147
Started
2017
with 2 others
Phase 2
3 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
7 of 17
Janssen Research & Development, LLC

Among the 17 studies testing esketamine in Depressive Disorder, Major, this one is the 9th largest by enrollment, is one of 3 that started in 2017, is one of 3 in phase 2, and was the 6th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 9 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing esketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral midazolam) in rapidly reducing the symptoms of major depressive disorder (MDD) including suicidal ideation in participants 12 to less than 18 years of age who are assessed to be at imminent risk for suicide.

Read the detailed description

This study will enroll participants with major depressive disorder (MDD) presenting with suicidal ideation who are assessed to be at imminent risk for suicide. The study will be conducted in 4 phases: a screening evaluation performed within 48 hours prior to Day 1 intranasal dose; a 25-day double-blind treatment phase (Days 1-25); an 8-week initial post-treatment phase (Days 25-81); and a subsequent phase to complete a full 6-month post-treatment follow-up (Days 81-200). Efficacy, safety, pharmacokinetic, biomarker, and pharmacogenomic evaluations will be performed in the study at defined schedule. The duration of the participant's participation will be approximately 29 weeks. If you or a loved one are having thoughts of suicide, please seek immediate medical help. Go to the emergency room or call the National Suicide Prevention Lifeline at 1-800-273-8255.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
9 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet (5th edition) {DSM-5} diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the mini international neuropsychiatric interview for children and adolescents (MINI KID)
  • Participant must have a children's depression rating scale-revised (CDRS-R) total score of equal or more than (>=) 58 predose on Day 1
  • As part of standard of care treatment, participant must agree to be hospitalized voluntarily for a recommended period of 5 days after randomization (may be shorter or longer if clinically warranted in the investigator's opinion)
  • As part of the newly initiated or optimized standard of care treatment, participant must agree to take one of the prescribed non- antidepressant medications (fluoxetine, escitalopram, sertraline; and 9-11 years old participants at US-sites only: fluoxetin [preferred], sertraline) at least during the double-blind treatment phase (Day 25)
  • As part of standard of care treatment, participant must agree to participate in a specific psychological intervention (individual cognitive behavioral therapy [CBT], interpersonal therapy, family therapy or psychodynamic psychotherapy) at least through the initial 8-week post-treatment follow-up period (Day 81)

Exclusion criteria

Exclusion Criteria:

  • Participants has a current diagnosis of bipolar (or related disorders), intellectual disability, autism spectrum disorder, conduct disorder, anorexia nervosa, oppositional defiant disorder, or obsessive compulsive disorder
  • Participants currently meets DSM-5 criteria for borderline personality disorder. Participants not meeting full DSM-5 criteria for borderline personality disorder but exhibiting recurrent suicidal gestures, threats, or self-mutilating behaviors should also be excluded
  • Participant has a current or prior DSM-5 diagnosis of a psychotic disorder or MDD with psychosis
  • Participant meets the DSM-5 severity criteria for moderate or severe substance or alcohol use disorder (except for nicotine or caffeine) within the 6 months before screening. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary
  • Participant has a history of seizure disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
147 participants (actual)

Study arms

  • Placebo comparator
    Oral Midazolam + Intranasal Placebo

    Participants will receive midazolam solution 0.125 milligram per kilogram (mg/kg) orally 2 times per week for 4 weeks and 3 intranasal doses of matched placebo to esketamine.

    Drug: Intranasal Placebo · Drug: Midazolam

  • Experimental
    Oral Placebo + Esketamine 84 mg

    Participants will receive intranasal esketamine 84 mg as 3 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.

    Drug: Midazolam Placebo Solution · Drug: Esketamine

  • Experimental
    Oral Placebo + Esketamine 56 mg

    Participants will receive intranasal esketamine 56 mg as 2 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.

    Drug: Midazolam Placebo Solution · Drug: Esketamine

  • Experimental
    Oral Placebo + Esketamine 28 mg

    Participants will receive intranasal esketamine 28 mg as 1 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.

    Drug: Midazolam Placebo Solution · Drug: Esketamine

Interventions

  • DrugIntranasal Placebo

    Participants will receive placebo as intranasal dose to match intranasal esketamine.

  • DrugMidazolam Placebo Solution

    Participants will receive placebo as oral dose to match midazolam drug.

  • DrugMidazolam

    Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.

  • Participants will receive esketamine at a dose of 28 mg as intranasal solution.

  • Participants will receive esketamine at a dose of 56 mg as intranasal solution.

  • Participants will receive esketamine at a dose of 84 mg as intranasal solution.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at 24 Hours Post First Dose (Day 2)

    The CDRS-R is a validated 17- item, clinician-rated instrument developed to assess depressive symptomatology in children. Scores were based on interviews with both the child and their caregiver. Of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5-point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome.

    Time frame: Baseline (predose on Day 1) and 24 hours post first dose on Day 1 (i.e., Day 2)

07

Results

Posted Apr 17, 2024

Participant flow

A total of 147 participants were randomized and treated. One participant (randomized to arm "Esketamine 84 mg+Placebo+standard of care \[SOC\]") was excluded from the efficacy analysis set, safety analysis set, and follow-up analysis set due to Good Clinical Practice (GCP) issue at the site.

Double-Blind Phase: Day 1 to Day 25
Participant flow — Double-Blind Phase: Day 1 to Day 25
MilestonePlacebo + Midazolam + SOCEsketamine 28 mg + Placebo + SOCEsketamine 56 mg + Placebo + SOCEsketamine 84 mg + Placebo + SOC
Started63293124
Safety analysis set63293123
Full efficacy analysis set63283123
Follow-up analysis set59292921
Completed59292922
Not completed4022
Withdrew: Withdrawal by parent/guardian0001
Withdrew: Other1010
Withdrew: Adverse event1000
Withdrew: Lack of efficacy2010
Withdrew: Subject refused further study treatment0001
Post-treatment Follow-up: Days 26 to 200
Participant flow — Post-treatment Follow-up: Days 26 to 200
MilestonePlacebo + Midazolam + SOCEsketamine 28 mg + Placebo + SOCEsketamine 56 mg + Placebo + SOCEsketamine 84 mg + Placebo + SOC
Started59292921
Completed48242118
Not completed11583
Withdrew: Withdrawal by parent/guardian1010
Withdrew: Other1031
Withdrew: Adverse event0100
Withdrew: Requires treatment with electroconvulsive therapy, transcranial magnetic stimulation, ketamine1000
Withdrew: Withdrawal by subject3320
Withdrew: Physician decision2020
Withdrew: Lost to follow-up2102
Withdrew: Death1000

Outcome measures

PrimaryChange From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at 24 Hours Post First Dose (Day 2)

The CDRS-R is a validated 17- item, clinician-rated instrument developed to assess depressive symptomatology in children. Scores were based on interviews with both the child and their caregiver. Of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5-point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome.

Time frame:
Baseline (predose on Day 1) and 24 hours post first dose on Day 1 (i.e., Day 2)
Reported as:
Mean · Units on a scale
Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at 24 Hours Post First Dose (Day 2)
Units on a scalePlacebo + Midazolam + SOCEsketamine 28 mg + Placebo + SOCEsketamine 56 mg + Placebo + SOCEsketamine 84 mg + Placebo + SOCPooled Esketamine 56 mg + Esketamine 84 mg
Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at 24 Hours Post First Dose (Day 2)-26.2 ± 16.72-29.6 ± 18.15-31.8 ± 12.92-30.3 ± 17.48-31.2 ± 14.90
Statistical analysis
  • Placebo + Midazolam + SOC vs Pooled Esketamine 56 mg + Esketamine 84 mg · ANCOVA · p = = 0.037 (Threshold for significance for p-value was 0.05.) · Difference of ls means: -5.8 · 95% CI -11.19 to -0.35
  • Placebo + Midazolam + SOC vs Esketamine 84 mg + Placebo + SOC · ANCOVA · p = = 0.123 (Threshold for significance for p-value was 0.05.) · Difference of ls mean: -5.7 · 95% CI -12.91 to 1.55
  • Placebo + Midazolam + SOC vs Esketamine 56 mg + Placebo + SOC · ANCOVA · p = = 0.072 (Threshold for significance for p-value was 0.05.) · Difference of ls means: -5.9 · 95% CI -12.25 to 0.53
  • Placebo + Midazolam + SOC vs Esketamine 28 mg + Placebo + SOC · Difference of ls means: -2.4 · 95% CI -9.08 to 4.19

Adverse events

Collected over Double Blind treatment phase: From Day 1 to Day 25; Follow-up phase: From Day 26 up to end of post-treatment follow-up phase (Day 200). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB: Placebo + Midazolam + SOC0/63 (0%)9/63 (14.3%)57/63 (90.5%)
DB: Esketamine 28 mg + Placebo + SOC0/29 (0%)4/29 (13.8%)26/29 (89.7%)
DB: Esketamine 56 mg + Placebo + SOC0/31 (0%)7/31 (22.6%)30/31 (96.8%)
DB: Esketamine 84 mg + Placebo + SOC0/23 (0%)1/23 (4.3%)23/23 (100%)
FU Phase: Placebo + Midazolam + SOC1/59 (1.7%)19/59 (32.2%)48/59 (81.4%)
FU Phase: Esketamine 28 mg + Placebo + SOC0/29 (0%)10/29 (34.5%)21/29 (72.4%)
FU Phase: Esketamine 56 mg + Placebo + SOC0/29 (0%)8/29 (27.6%)19/29 (65.5%)
FU Phase: Esketamine 84 mg + Placebo + SOC0/21 (0%)7/21 (33.3%)14/21 (66.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventDB: Placebo + Midazolam + SOCDB: Esketamine 28 mg + Placebo + SOCDB: Esketamine 56 mg + Placebo + SOCDB: Esketamine 84 mg + Placebo + SOCFU Phase: Placebo + Midazolam + SOCFU Phase: Esketamine 28 mg + Placebo + SOCFU Phase: Esketamine 56 mg + Placebo + SOCFU Phase: Esketamine 84 mg + Placebo + SOC
Suicide AttemptPsychiatric disorders5/631/295/311/239/593/295/294/21
Suicidal IdeationPsychiatric disorders3/633/292/310/234/595/293/293/21
Depression SuicidalPsychiatric disorders1/631/290/310/233/592/291/291/21
Intentional Self-InjuryPsychiatric disorders0/630/290/310/232/592/290/291/21
Alcohol PoisoningInjury, poisoning and procedural complications0/630/290/310/230/590/290/291/21
Humerus FractureInjury, poisoning and procedural complications0/630/290/310/230/590/290/291/21
Intentional OverdoseInjury, poisoning and procedural complications0/630/290/310/230/590/290/291/21
Pelvic FractureInjury, poisoning and procedural complications0/630/290/310/230/590/290/291/21
Food RefusalMetabolism and nutrition disorders0/630/290/310/230/590/290/291/21
Status MigrainosusNervous system disorders0/630/290/310/230/590/290/291/21
Most frequent other events
Showing 10 of 61
Most frequent other events
EventDB: Placebo + Midazolam + SOCDB: Esketamine 28 mg + Placebo + SOCDB: Esketamine 56 mg + Placebo + SOCDB: Esketamine 84 mg + Placebo + SOCFU Phase: Placebo + Midazolam + SOCFU Phase: Esketamine 28 mg + Placebo + SOCFU Phase: Esketamine 56 mg + Placebo + SOCFU Phase: Esketamine 84 mg + Placebo + SOC
DizzinessNervous system disorders27/6316/2916/3116/233/590/292/290/21
NauseaGastrointestinal disorders11/638/2915/3113/239/593/293/291/21
DissociationPsychiatric disorders11/6312/2912/3111/231/591/291/290/21
HeadacheNervous system disorders18/6310/2913/317/2312/5910/297/293/21
DysgeusiaNervous system disorders15/6310/298/319/230/590/290/290/21
SomnolenceNervous system disorders24/6310/299/318/232/590/291/290/21
Intentional Self-InjuryPsychiatric disorders12/636/296/315/2321/597/293/297/21
VomitingGastrointestinal disorders4/635/297/316/234/593/290/290/21
HypoaesthesiaNervous system disorders2/635/298/314/230/590/290/290/21
Hypoaesthesia OralGastrointestinal disorders0/636/296/315/231/590/290/290/21

Baseline characteristics

All baseline characteristics were analyzed on the safety analysis set which included all randomized participants who received at least one dose of DB study drug.

Age, Continuous
Age, Continuous(years)Placebo + Midazolam + SOCEsketamine 28 mg + Placebo + SOCEsketamine 56 mg + Placebo + SOCEsketamine 84 mg + Placebo + SOCTotal
Mean15.2 ± 1.4514.9 ± 1.3314.8 ± 1.5214.3 ± 1.4314.9 ± 1.46
Age, Customized
Age, Customized(Participants)Placebo + Midazolam + SOCEsketamine 28 mg + Placebo + SOCEsketamine 56 mg + Placebo + SOCEsketamine 84 mg + Placebo + SOCTotal
Children (2-11 years)00000
Adolescents (12-17 years)63293123146
Adults (18-64 years)00000
From 65 to 84 years00000
85 years and over00000
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Midazolam + SOCEsketamine 28 mg + Placebo + SOCEsketamine 56 mg + Placebo + SOCEsketamine 84 mg + Placebo + SOCTotal
Female48242517114
Male1556632
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + Midazolam + SOCEsketamine 28 mg + Placebo + SOCEsketamine 56 mg + Placebo + SOCEsketamine 84 mg + Placebo + SOCTotal
Hispanic or Latino1678334
Not Hispanic or Latino46192019104
Unknown or Not Reported13318
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + Midazolam + SOCEsketamine 28 mg + Placebo + SOCEsketamine 56 mg + Placebo + SOCEsketamine 84 mg + Placebo + SOCTotal
American Indian or Alaska Native20002
Asian10203
Native Hawaiian or Other Pacific Islander00000
Black or African American641415
White53252317118
More than one race00202
Unknown or Not Reported10326
08

Study locations

51 sites
  • Institute of Living/ Hartford Hospital
    Hartford, Connecticut 06106, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Atlanta Behavioral Research, LLC
    Atlanta, Georgia 30338, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Neuroscience Research Institute
    Winfield, Illinois 60190, United States
  • Beacon Medical Group Clinical Research
    South Bend, Indiana 46617, United States
  • University of Iowa, Carver College of Medicine
    Iowa City, Iowa 52242, United States
  • Lake Charles Clinical Trials
    Lake Charles, Louisiana 70629, United States
  • Sheppard Pratt Health System
    Baltimore, Maryland 21204, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • State University of New York at Buffalo
    Buffalo, New York 14215, United States
  • University North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati Hospital
    Cincinnati, Ohio 45219, United States
  • University Hospital of Cleveland
    Cleveland, Ohio 44106, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9063, United States
  • Hopital Erasme
    Brussels, 1070, Belgium
  • Trial Tech Tecnologia em Pesquisas com Medicamentos
    Curitiba, 80240-280, Brazil
  • Hospital Universitario Professor Edgar Santos
    Salvador, 40110-060, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos
    Sao Bernardo do Campo, 09715-090, Brazil
  • Hospital São Sebastião
    Turvo, 88930-000, Brazil
  • Mental Health Center - Rousse
    Ruse, 7003, Bulgaria
  • Multiprofile Hospital for Active Treatment - MHAT Sveta Marina EAD
    Varna, Bulgaria
  • Hospices Civils de Lyon HCL
    Bron, 69677, France
  • CHRU Lille - Hôpital Fontan 1
    Lille, 59000, France
  • CHU Nantes
    Nantes, 44093, France
  • Hôpital Universitaire Pitié-Salpêtrière
    Paris, 75013, France
  • Hopital Sainte Anne
    Paris, 75014, France
  • Hôpital Robert Debré
    Paris, 75019, France
  • Vadaskert Gyermek es Ifjusagpszichiatriai Korhaz es Szakambulancia
    Budapest, Hungary
  • Szegedi Tudomanyegyetem
    Szeged, Hungary
  • Azienda Ospedaliera G. Brotzu
    Cagliari, 09134, Italy
  • OSP RIUNITI-DIP Donna- Bambino
    Foggia, 71122, Italy
  • Ospedale di Merano
    Merano, 39012, Italy
  • Azienda Ospedaliera Universitaria Policlinico G. Martino
    Messina, 98125, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, 80138, Italy
  • IRCCS C. Mondino, Istituto Neurologico Nazionale, Fondazione
    Pavia, 27100, Italy
  • Irccs Burlo-Garofalo
    Trieste, 34137, Italy
  • Klinika Psychiatrii Dzieci i Mlodziezy, CM UJ
    Krakow, 31-501, Poland
  • Dzieciecy Szpital Kliniczny im Jozefa Polikarpa Brudzinskiego
    Warszawa, 02 091, Poland
  • Instytut Psychiatrii i Neurologii Klinika Psychiatrii Dzieci i Mlodziezy
    Warszawa, 02-957, Poland
  • Hosp Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hosp. Sant Joan de Deu
    Esplugues de Llobregat, 08950, Spain
  • Hosp. Gral. Univ. Gregorio Maranon
    Madrid, 28007, Spain
  • Hosp. Infantil Univ. Nino Jesus
    Madrid, 28009, Spain
  • Hosp. Univ. Pta. de Hierro Majadahonda
    Majadahonda, 28222, Spain
  • Hosp. Univ. Central de Asturias
    Oviedo, 33011, Spain
  • Clinica Univ. de Navarra
    Pamplona, 31008, Spain
  • Corporacio Sanitari Parc Tauli
    Sabadell, 08208, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Mar 2023, 65 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 65 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2017
First posted
Jun 14, 2017
StartActual
Oct 5, 2017
Primary completionActual
Mar 31, 2023
CompletionActual
Mar 31, 2023
Results first posted
Apr 17, 2024
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03185819
Responsible party
Sponsor
First posted
Jun 14, 2017
Start date
Oct 5, 2017
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023
Results posted
Apr 17, 2024
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion